The bile acid receptor FXR is a modulator of intestinal innate immunity
about
Breast Milk and Solid Food Shaping Intestinal ImmunityThe role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspectiveBile Acid Metabolism and Signaling in Cholestasis, Inflammation, and CancerBile acid metabolism and signalingFXR signaling in the enterohepatic systemProbiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activationA prospective view of animal and human FasciolosisBile acid nuclear receptor FXR and digestive system diseasesBile acid signaling in metabolic disease and drug therapyUrsodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytesThe bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammationThe bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitisHost-gut microbiota metabolic interactionsInflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host.Commensal bacteria at the interface of host metabolism and the immune system.Gut Microbiota Co-microevolution with Selection for Host Humoral ImmunitySodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptorFarnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.Colonic inflammation and secondary bile acids in alcoholic cirrhosisAssociation of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease.Tissue specific induction of p62/Sqstm1 by farnesoid X receptor.Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.Recent advances in the development of farnesoid X receptor agonistsPharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis.Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modificationsBacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes.Bile retinoids imprint intestinal CD103+ dendritic cells with the ability to generate gut-tropic T cells.A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity.Pregnane X receptor modulates the inflammatory response in primary cultures of hepatocytesActivation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in miceFXR protects lung from lipopolysaccharide-induced acute injuryA tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor.Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expressionFunctions of innate immune cells and commensal bacteria in gut homeostasis.Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice.FXR and liver carcinogenesis
P2860
Q26782801-CDD2855E-DAC6-45AB-B3E4-E86884A9AC69Q26795563-79B2A651-50F3-4BA8-B17A-876F5E677E6EQ26800206-E3BE4557-E00F-45D9-9B3A-BC2B5A3C772BQ27002873-A998CBAE-A05A-411D-8E82-6D2DA44A362EQ27014753-B51DB80F-4CA3-4192-B523-8DD2EC6DE53FQ27327276-9F42EE26-C862-42F9-BE0C-DE59EF83D14BQ28067643-84C73917-9372-4C67-854E-2A56838AE33DQ28085493-08A6015D-879C-4396-A48A-46B755712A9BQ28244875-FC00A078-51C4-49B4-A184-3A1FDE0CD2AFQ28535795-6C2F14C6-E0F2-4B57-8248-12A31A432918Q28585275-C606EAF3-B343-4FDA-BED3-37442E79B4CDQ28590901-1F72546D-8121-4A02-A5FC-E82998355C82Q29615104-C0AF5E08-BC90-4F6A-ADD2-159E4166A4B6Q30234950-CBB90CC3-6500-4BB5-9215-6E6BA9F750D3Q30412140-0FEDCCBB-ED66-4134-B2FD-CE861B8E4416Q33578547-77D9BC3F-6F5B-4CC9-A1FA-CE4DEA8E15F0Q33867263-67505BA1-5EA3-4780-A68D-4C4B09D0DB45Q33884592-2D3A2803-4423-4DC8-B688-296B92CDF91FQ34009566-0AB5A248-9F8C-4F46-A3A3-7AC8B3D9A274Q34121950-3FFC8DB2-8DFD-41D6-AEAE-C01C9346F5A9Q34396606-6CE08EBF-05E1-428F-BB20-8C664ABCE784Q34405939-EDB71CF6-6193-46DF-B9E6-493A3010D098Q34425909-C9519ABC-1757-429E-86B3-B4C452CFDEF4Q34428997-756E881F-2B97-4D07-AA60-41A202B2ECB3Q34464043-4C605522-7832-44AE-BE49-BE499384264AQ34493836-78BF8B1E-4D8E-4552-A7D4-B50842F2B63BQ34627935-EBFDDB2C-49AC-4570-8E69-61E8B5FFCF8DQ34694229-AC6E9CB5-9ECB-4728-B16B-F8AB1671066EQ34724632-E3AB77AE-2853-4383-91D4-ED50182E494EQ35087813-01848A03-1A80-4F28-8F2F-CDE9F66ECC57Q35109579-71B3150A-CFBB-4128-BA64-8E2DC4FDBD0DQ35156371-160871CE-318D-44AA-AF45-3BB6EC70BDC5Q35635951-499A910E-1882-4876-8C47-FFB8EE5BFB8FQ35640697-BA7E9A4D-225F-402A-A7D6-BE10DDD4EE93Q35675180-90023C31-CBC1-4C24-A796-6630E5C6F425Q35724871-18785839-3596-49E2-8E35-9872D8A4F007Q35786712-E82FA6D6-E679-4367-9288-C012AB29F695Q35854795-88D90D26-0A42-43AB-92F8-05EB2120F7B6Q35931282-5432810C-A641-4B35-B243-0CB710323560Q36063712-B1049F27-6EB6-4CC5-BD23-B858B48B2AA1
P2860
The bile acid receptor FXR is a modulator of intestinal innate immunity
description
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im November 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2009/11/15)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd op 2009/11/15)
@nl
наукова стаття, опублікована в листопаді 2009
@uk
مقالة علمية (نشرت في 15-11-2009)
@ar
name
The bile acid receptor FXR is a modulator of intestinal innate immunity
@ast
The bile acid receptor FXR is a modulator of intestinal innate immunity
@en
The bile acid receptor FXR is a modulator of intestinal innate immunity
@nl
type
label
The bile acid receptor FXR is a modulator of intestinal innate immunity
@ast
The bile acid receptor FXR is a modulator of intestinal innate immunity
@en
The bile acid receptor FXR is a modulator of intestinal innate immunity
@nl
prefLabel
The bile acid receptor FXR is a modulator of intestinal innate immunity
@ast
The bile acid receptor FXR is a modulator of intestinal innate immunity
@en
The bile acid receptor FXR is a modulator of intestinal innate immunity
@nl
P2093
P3181
P356
P1476
The bile acid receptor FXR is a modulator of intestinal innate immunity
@en
P2093
Andrea Mencarelli
Barbara Renga
Eleonora Distrutti
Piero Vavassori
P304
P3181
P356
10.4049/JIMMUNOL.0803978
P407
P577
2009-11-15T00:00:00Z